Dietary Ingredient Studies For Health Benefits Could Be Fenced In By US FDA IND Proposal
Executive Summary
Proposed rule introduces two exemptions agency would allow from needing IND clearance for clinical investigations to evaluate food, supplements or cosmetics. Both begin with basic requirement of trial not intended to support drug development plan or labeling change that would make a food, dietary ingredient or cosmetic an unlawfully marketed drug.
You may also be interested in...
Cosmetic Clinical Trials Can Explore Drug Effects Without IND – US FDA Proposed Rule
The proposed rule addresses objections raised by industry in response to the agency’s former position set forth in 2013 guidance. The FDA now proposes two investigational new drug exemption pathways which it says will reduce regulatory burdens while ensuring that study subjects are protected.
Still No Appetite At US FDA For CBD In Food
Three years after similar warnings to make same impression, FDA warns five firms about using in food or beverage products CBD, the cannabinoid most commonly found in US, and delta-8 THC, a subject of ongoing discussion over whether it qualifies as hemp. One firm also warned about CBD in sunscreen.
FDA Expects Closing Gap On NDI Notifications To Open Window Wider On Supplements Sold In US
FDA regulatory framework for VMS product manufacturing and marketing provides little pre-market transparency into what’s available in US, but it’s clear from post-market monitoring by the Office of Dietary Supplement Programs that compliance with the NDI notification requirement is lax.